Clinical pharmacokinetics and pharmacodynamics of erythropoiesis- stimulating agents

Clinical Pharmacokinetics

Volumn 52, Issue 12, 2013, Pages 1063-1083

  Doshi, Sameer ^a   Krzyzanski, Wojciech ^b   Yue, Susan ^a   Elliott, Steven ^a   Chow, Andrew ^a   Pérez Ruixo, Juan José ^a  

^a AMGEN INC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ASIALOGLYCOPROTEIN RECEPTOR; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; MACROGOL; NM 294; NM 385; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHARMACOLOGICAL BIOMARKER; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; ROMIPLOSTIM; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANEMIA; AREA UNDER THE CURVE; BINDING AFFINITY; BODY WEIGHT; CANCER CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TOLERANCE; ERYTHROCYTE COUNT; ERYTHROPOIESIS; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; MINIMUM EFFECTIVE CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TIME;

ANIMALS; BIOLOGICAL AVAILABILITY; ERYTHROPOIESIS; HEMATINICS; HUMANS;

EID: 84890479511     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0098-x     Document Type: Review

References (221)

1. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. Nature. 1957;179(4560):633-4.
2. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977;252(15):5558-64.
3. Reissmann KR. Studies on the mechanism of erythropoietic stimulation in parabiotic rats during hypoxia. Blood. 1950;5(4):372-80.
4. Fisher JW, Birdwell BJ. The production of an erythropoietic factor by the in situ perfused kidney. Acta Haematol. 1961;26(4):224-32.
5. Kuratowska Z, Lewartowski B, Michalak E. Studies on the production of erythropoietin by isolated perfused organs. Blood. 1961;18:527-34.
6. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA. 1985;82(22):7580-4.
7. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806-10.
8. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50(6):702-12.
9. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008;36(12):1573-84.
10. Egrie JC, Strickland TW, Lane J, Aoki K, Cohen AM, Smalling R, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 1986;172(3-5):213-24.
11. Imai N, Kawamura A, Higuchi M, Oh-eda M, Orita T, Kawaguchi T, et al. Physicochemical and biological comparison of recombinant human erythropoietin with human urinary erythropoietin. J Biochem. 1990;107(3):352-9.
12. Rency MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin: identification of des-arginine 166 erythropoietin. J Biochem. 1987;262:17156-63.
13. Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol. 2000;1(1):11-31.
14. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001;16(Suppl 3):3-13.
15. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10(11):2392-5.
16. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21(4):414-21.
17. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci. 2005;94(8):1626-35.
18. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31(4):290-9.
19. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94(16):1211-20.
20. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40(1):110-8.
21. Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4(6):436-40.
22. Gascon P, Pirker R, Del Mastro L, Durrwell L. Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. Ann Oncol. 2010;21(10):2029-39.
23. Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology. 2008;81(1):63-9.
24. European Medicines Agency. Abseamed: EPAR summary for the public (2012). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000727/WC500020663.pdf. Accessed 19 Jun 2013.
25. European Medicines Agency. Binocrit: EPAR summary for the public (2012). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000725/WC500053613.pdf. Accessed 19 Jun 2013.
26. European Medicines Agency. Epoetin Alfa HEXAL: EPAR summary for the public (2012). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Summary-for-the-public/human/000726/WC500028285.pdf. Accessed 19 Jun 2013.
27. European Medicines Agency. Retacrit: EPAR summary for the public (2011). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000872/WC500054372.pdf. Accessed 19 Jun 2013.
28. European Medicines Agency. Silapo: EPAR summary for the public (2012). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the- public/human/000760/WC500050912.pdf. Accessed 19 Jun 2013.
29. European Medicines Agency. Silapo: scientific discussion (2007). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000760/WC500050914.pdf. Accessed 19 Jun 2013.
30. European Medicines Agency. Retacrit: scientific discussion (2007). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/ human/000872/WC500054374.pdf. Accessed 19 Jun 2013.
31. Erslev AJ. In vitro production of erythropoietin by kidneys perfused with a serum-free solution. Blood. 1974;44(1):77-85.
32. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230-7.
33. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA. 1991;88(13):5680-4.
34. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395(6701):511-6.
35. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood. 1997;89(2):493-502.
36. D'Andrea AD, Lodish HF, Wong GG. Expression cloning of the murine erythropoietin receptor. Cell. 1989;57(2):277-85.
37. D'Andrea AD, Zon LI. Erythropoietin receptor: subunit structure and activation. J Clin Invest. 1990;86(3):681-7.
38. Elliott S, Sinclair AM. The effect of erythropoietin on normal and neoplastic cells. Biologics. 2012;6:163-89.
39. Fraser JK, Lin FK, Berridge MV. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line. HEL Exp Hematol. 1988;16(10):836-42.
40. Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem. 1987;262(12):5554-62.
41. Matthews DJ, Topping RS, Cass RT, Giebel LB. A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci USA. 1996;93(18):9471-6.
42. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry (Mosc). 1996;35(5):1681-91.
43. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992;72(2):449-89.
44. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228(1):1-14.
45. Fisher JW. Landmark advances in the development of erythropoietin. Exp Biol Med (Maywood). 2010;235(12):1398-411.
46. Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood. 1989;74(1):103-9.
47. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood. 2005;105(2):600-8.
48. Gross AW, Lodish HF. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem. 2006;281(4):2024-32.
49. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990;248(4953):378-81.
50. Rodak B, Fritsma G, Doig K. Hematology: clinical principles and applications. 3rd ed. Philadelphia: Elsevier Health Sciences; 2007.
51. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301-15.
52. Bohlius J, Tonia T, Schwarzer G. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol. 2011;125(1-2):55-67.
53. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, et al. Anti-EPO receptor antibodies do not predict EPO receptor expression. Blood. 2006;107(5):1892-5.
54. Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, et al. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010;115(21):4254-63.
55. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010;115(21):4264-72.
56. Fisher JW, Koury S, Ducey T, Mendel S. Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol. 1996;95(1):27-32.
57. Koury MJ, Bondurant MC. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol. 1988;137(1):65-74.
58. Spivak JL. The biology and clinical applications of recombinant erythropoietin. Semin Oncol. 1998;25(3 Suppl 7):7-11.
59. Spivak JL. Changing paradigms in anemia management. Adv Stud Med. 2002;22:610-9.
60. Besarab A. Physiological and pharmacodynamic considerations for route of EPO administration. Semin Nephrol. 2000;20(4):364-74.
61. Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, Chanal JL. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes: blood sampling and doping control. Br J Clin Pharmacol. 1996;42(3):355-64.
62. Koopman MG, Koomen GC, Krediet RT, de Moor EA, Hoek FJ, Arisz L. Circadian rhythm of glomerular filtration rate in normal individuals. Clin Sci (Lond). 1989;77(1):105-11.
63. Wide L, Bengtsson C, Birgegard G. Circadian rhythm of erythropoietin in human serum. Br J Haematol. 1989;72(1):85-90.
64. Pasqualetti P, Collacciani A, Casale R. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes. Eur Rev Med Pharmacol Sci. 2000;4(5-6):111-5.
65. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-8.
66. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992-1000.
67. Erslev AJ. Erythropoietin. N Engl J Med. 1991;324(19):1339-44.
68. Thorling EB, Ersbak J. Erythrocytosis and hypernephroma. Scand J Haematol. 1964;1:38-46.
69. Kazal LA, Erslev AJ. Erythropoietin production in renal tumors. Ann Clin Lab Sci. 1975;5(2):98-109.
70. Ueno M, Seferynska I, Beckman B, Brookins J, Nakashima J, Fisher JW. Enhanced erythropoietin secretion in hepatoblastoma cells in response to hypoxia. Am J Physiol. 1989;257(4 Pt 1):C743-9.
71. Trimble M, Caro J, Talalla A, Brain M. Secondary erythrocytosis due to a cerebellar hemangioblastoma: demonstration of erythropoietin mRNA in the tumor. Blood. 1991;78(3):599-601.
72. Fried W, Ward HP, Hopeman AR. Leiomyoma and erythrocytosis: a tumor producing a factor which increases erythropoietin production. Report of case. Blood. 1968;31(6):813-6.
73. Davies SV, Fegan CD, Kendall R, Beguin Y, Cavill I. Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity. Clin Lab Haematol. 1995;17(2):139-44.
74. Pavlovic-Kentera V, Milenkovic P, Ruvidic R, Jovanovic V, Biljanovic-Paunovic L. Erythropoietin in aplastic anemia. Blut. 1979;39(5):345-50.
75. Hammond D, Shore N, Movassaghi N. Production, utilization and excretion of erythropoietin. I: Chronic anemias. II: Aplastic crisis. 3: Erythropoietic effects of normal plasma. Ann N Y Acad Sci. 1968;149(1):516-27.
76. Alexanian R. Erythropoietin excretion in bone marrow failure and hemolytic anemia. J Lab Clin Med. 1973;82(3):438-45.
77. Embury SH, Garcia JF, Mohandas N, Pennathur-Das R, Clark MR. Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia. N Engl J Med. 1984;311(5):291-5.
78. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol. 2011;6:165-92.
79. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 1990;76(9):1718-22.
80. Boxenbaum H. Pharmacokinetics tricks and traps: flip-flop models. J Pharm Pharm Sci. 1998;1(3):90-1.
81. Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295-306.
82. Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010;12(4):729-40.
83. Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89(3):297-310.
84. Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res. 1990;7(2):167-9.
85. Leak LV. The structure of lymphatic capillaries in lymph formation. Fed Proc. 1976;35(8):1863-71.
86. McLennan DN, Porter CJ, Edwards GA, Martin SW, Heatherington AC, Charman SA. Lymphatic absorption is the primary contributor to the systemic availability of epoetin alfa following subcutaneous administration to sheep. J Pharmacol Exp Ther. 2005;313(1):345-51.
87. Olsson-Gisleskog P, Jacqmin P, Perez-Ruixo JJ. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet. 2007;46(2):159-73.
88. Ait-Oudhia S, Vermeulen A, Krzyzanski W. Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients. Biopharm Drug Dispos. 2011;32(1):1-15.
89. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci. 2005;26(3-4):295-306.
90. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004;44(9):991-1002.
91. Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol. 1994;46(4):333-7.
92. Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol. 2007;47(11):1390-7.
93. McLennan DN, Porter CJ, Edwards GA, Heatherington AC, Martin SW, Charman SA. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. Pharm Res. 2006;23(9):2060-6.
94. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005;41(8):1140-9.
95. Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet. 2006;45(5):503-10.
96. Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J. 2006;8(3):E552-63.
97. Agoram B, Sutjandra L, Sullivan JT. Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol. 2007;63(1):41-52.
98. Doshi S, Chow A, Perez Ruixo JJ. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. J Clin Pharmacol. 2010;50(9 Suppl):75S-90S.
99. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev. 2003;55(10):1261-77.
100. European Medicines Agency. Mircera: EPAR - product information (2012). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000739/WC500033672.pdf. Accessed 19 Jun 2012.
101. Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. J Clin Pharmacol. 2007;47(11):1390-7.
102. Sutjandra L, Rodriguez RD, Doshi S, Ma M, Peterson MC, Jang GR, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793-807.
103. Kakkar T, Sung C, Gibiansky L, Vu T, Narayanan A, Lin SL, et al. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res. 2011;28(10):2530-42.
104. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol. 1990;29(6):709-13.
105. Jensen JD, Madsen JK, Jensen LW, Pedersen EB. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol. 1994;5(2):177-85.
106. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs. 2004;64(5):499-509.
107. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998;64(4):412-23.
108. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol. 2001;57(5):411-8.
109. Bommer J, Barth HP, Zeier M, Mandelbaum A, Bommer G, Ritz E, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol. 1991;88:136-43.
110. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339(9):578-83.
111. Kampf D, Kahl A, Passlick J, et al. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration: preliminary results. Contrib Nephrol. 1989;76:106-11.
112. Perez-Ruixo JJ, Cucala-Ramos M, Garcia-Gonzalo E, Del Val Romero B, Valveny N. Between-subjects hemoglobin variability is not associated with the erythropoiesis-stimulating agent used to treat anemia in dialysis: a meta-analysis. Br J Clin Pharmacol. 2012 (In press).
113. Macdougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet. 1991;20(2):99-113.
114. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther. 1990;47(5):557-64.
115. Kompella A. Pharmacokinetics of peptide and protein drugs. In: Lee V, editor. Peptide and protein drug delivery. New York: Marcel Dekker; 1991. p. 391-84.
116. Braeckman R. Pharmacokinetics and pharmacodynamics of protein therapeutics. In: Reid E, editor. Peptides and protein drug analysis. New York: Marcel Dekker; 2000. p. 633-69.
117. Kinoshita H, Ohishi N, Kato M, Tokura S, Okazaki A. Pharmacokinetics and distribution of recombinant erythropoietin in rats. Arzneimittelforschung. 1992;42(2):174-8.
118. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood. 1989;73(1):90-9.
119. Uji Y, Hirashima K, Hirasawa Y, Tohira Y, Mizuno K. Recombinant erythropoietin phase I clinical study - single intravenous administration. Med Consult N Rem. 1989;26:1-28.
120. Uji Y, Hirashima K, Hirasawa Y, Tohira Y, Mizuno K. Recombinant erythropoietin phase I clinical study - multiple intravenous administration. Med Consult N Rem. 1989;26:29-44.
121. Woo S, Jusko WJ. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metab Dispos. 2007;35(9):1672-8.
122. Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 2002;72(5):546-55.
123. Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer. 2001;84(Suppl 1):11-6.
124. Yoon WH, Park SJ, Kim IC, Lee MG. Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol. 1997;96(2):227-40.
125. Jang G. Darbepoetin alfa (Aranesp) pharmacokinetics is comparable in chronic kidney disease (CKD) patients receiving and not receiving dialysis, in pediatric patients and in healthy adults. American Society of Nephrology 38th Annual Renal Week Meeting; 8-13 November 2005; Philadelphia.
126. Nielsen OJ, Egfjord M, Hirth P. The metabolism of recombinant erythropoietin in the isolated perfused rat liver. Liver. 1990;10(6):343-9.
127. 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther. 1996;279(3):1205-10.
128. Jensen JD, Jensen LW, Madsen JK, Poulsen L. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol. 1995;54(2):111-6.
129. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 2001;298(2):820-4.
130. Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, et al. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther. 2007;81(6):873-9.
131. Heatherington AC, Dittrich C, Sullivan JT, Rossi G, Schueller J. Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. Clin Pharmacokinet. 2006;45(2):199-211.
132. Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, et al. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. J Pharm Sci. 2009;98(6):2198-211.
133. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, et al. Control of rHuEPO biological activity: the role of carbohydrate. Exp Hematol. 2004;32(12):1146-55.
134. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214-21.
135. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy. 2003;23(8 Pt 2):3S-8S.
136. Jolling K, Ruixo JJ, Hemeryck A, Piotrovskij V, Greway T. Population pharmacokinetic analysis of pegylated human erythropoietin in rats. J Pharm Sci. 2004;93(12):3027-38.
137. Jolling K, Perez Ruixo JJ, Hemeryck A, Vermeulen A, Greway T. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci. 2005;24(5):465-75.
138. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis: application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci. 1995;84(6):760-7.
139. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther. 1997;283(2):520-7.
140. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther. 2003;306(1):324-31.
141. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, et al. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos. 2004;25(4):149-56.
142. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS. A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos. 1999;20(4):217-23.
143. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, Lowe LS. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol. 1996;80(1):140-8.
144. Doshi S, Perez-Ruixo JJ, Jang GR, Chow AT. Pharmacokinetics of erythropoiesis-stimulating agents. In: Molineaux G, Foote MA, Elliott S, editors. Erythropoietins and erythropoiesis: molecular, cellular, preclinical, and clinical biology. 2nd ed. Basel: Birkhauser Verlag AG; 2009. p. 195-224.
145. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507-32.
146. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589-96.
147. Woo S, Krzyzanski W, Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn. 2007;34(6):849-68.
148. Wagner JG. Biopharmaceutics and relevant pharmacokinetics. Hamilton: Drug Intelligence Publications; 1971.
149. Yan X, Krzyzanski W. Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2012;39(2):141-6.
150. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol. 1990;66(2):83-6.
151. Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, et al. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Ann Intern Med. 1989;110(2):108-14.
152. Neumayer HH, Brockmoller J, Fritschka E, Roots I, Scigalla P, Wattenberg M. Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis. Contrib Nephrol. 1989;76:131-41 (discussion 41-2).
153. Yan X, Lowe PJ, Fink M, Berghout A, Balser S, Krzyzanski W. Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575. J Clin Pharmacol. 2012;52(11):1624-44.
154. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011;58(4):591-8.
155. Hartley C, Elliott S, Begley CG, McElroy P, Sutherland W, Khaja R, et al. Kinetics of haematopoietic recovery after dose-intensive chemo/radiotherapy in mice: optimized erythroid support with darbepoetin alpha. Br J Haematol. 2003;122(4):623-36.
156. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B, Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19(11):2865-74.
157. Sawada K, Krantz SB, Kans JS, Dessypris EN, Sawyer S, Glick AD, et al. Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin. J Clin Invest. 1987;80(2):357-66.
158. Tepperman AD, Curtis JE, McCulloch EA. Erythropietic colonies in cultures of human marrow. Blood. 1974;44(5):659-69.
159. Elliott S, Busse L, McCaffery I, Rossi J, Sinclair A, Spahr C, et al. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. J Immunol Methods. 2010;352(1-2):126-39.
160. McArthur GA, Longmore GD, Klingler K, Johnson GR. Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to EPO after normal hematopoietic cell transfection with EPOR. Exp Hematol. 1995;23(7):645-54.
161. Song SH, Groom AC. Sequestration and possible maturation of reticulocytes in the normal spleen. Can J Physiol Pharmacol. 1972;50(5):400-6.
162. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;77(12):2583-90.
163. Berlin NI, Berk PD. The biological life of red cell. In: Surgenor DM, editor. The red blood cell biology. New York: Academic Press; 1975. p. 975-1020.
164. Glader B. Destruction of erythrocytes. In: Greer JP, Rodgers GM, Foerster J, Paraskevas F, Lekens JN, Glader B, editors. Wintrobe's clinical hematology, vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 249-65.
165. Alfrey CP, Rice L, Udden MM, Driscoll TB. Neocytolysis: physiological down-regulator of red-cell mass. Lancet. 1997;349(9062):1389-90.
166. Willekens FL, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, Bos HJ, Bosman GJ, van den Bos AG, et al. Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation. Blood. 2003;101(2):747-51.
167. Adamson JW. The kidney and erythropoiesis. Am J Med. 1968;44:715-33.
168. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989;35(1):134-48.
169. McGonigle RJ, Husserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int. 1984;25(2):430-6.
170. Joske RA, McAlister JM, Prankerd TA. Isotope investigations of red cell production and destruction in chronic renal disease. Clin Sci (Lond). 1956;15(4):511-22.
171. Loge JP, Lange RD, Moore CV. Characterization of the anemia associated with chronic renal insufficiency. Am J Med. 1958;24(1):4-18.
172. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med. 1977;87(6):710-3.
173. Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant. 2002;17(9):1621-7.
174. Nissenson AR, Nimer SD, Wolcott DL. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med. 1991;114(5):402-16.
175. Adamson JW, Eschbach JW. Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med. 1990;41:349-60.
176. Radtke HW, Rege AB, LaMarche MB, Bartos D, Bartos F, Campbell RA, et al. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest. 1981;67(6):1623-9.
177. Kushner DS, Beckman BS, Fisher JW. Do polyamines play a role in the pathogenesis of the anemia of end-stage renal disease? Kidney Int. 1989;36(2):171-4.
178. Meytes D, Bogin E, Ma A, Dukes PP, Massry SG. Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981;67(5):1263-9.
179. Kato A, Hishida A, Kumagai H, Furuya R, Nakajima T, Honda N. Erythropoietin production in patients with chronic renal failure. Ren Fail. 1994;16(5):645-51.
180. Ross RP, McCrea JB, Besarab A. Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO J. 1994;40(3):M880-5.
181. Nowrousian MR. Pathophysiology of anemia in cancer. In: Nowrousian MR, editor. Human erythropoietin (rhHEPO) in clinical oncology scientific and clinical aspects of anemia in cancer. Wien: Springer; 2008. p. 149-88.
182. Mitlyng BL, Singh JA, Furne JK, Ruddy J, Levitt MD. Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. Am J Hematol. 2006;81(6):432-8.
183. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689-92.
184. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol. 2001;28(2 Suppl 8):1-6.
185. Endo Y, Nagai H, Watanabe Y, Ochi K, Takagi T. Heat-induced aggregation of recombinant erythropoietin in the intact and deglycosylated states as monitored by gel permeation chromatography combined with a low-angle laser light scattering technique. J Biochem. 1992;112(5):700-6.
186. Pedain C, Herrero J, Kunzel W. Serum erythropoietin levels in ovarian cancer patients receiving chemotherapy. Eur J Obstet Gynecol Reprod Biol. 2001;98(2):224-30.
187. Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006;13(27):3351-7.
188. McKenzie S. Textbook of hematology. 2nd ed. Baltimore: Williams & Wilkins; 1996.
189. Cazzola M, Ponchio L, Pedrotti C, Farina G, Cerani P, Lucotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica. 1996;81(5):434-41.
190. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci. 2000;37(2):93-130.
191. Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006;108(6):1830-4.
192. Perez-Ruixo JJ, Krzyzanski W, Hing J. Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet. 2008;47(6):399-415.
193. Perez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA, et al. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin Pharmacokinet. 2009;48(9):601-13.
194. Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol. 2008;48(1):43-52.
195. Amgen Inc. Epogen® (epoetin alfa): product information (2011). http://www.epogen.com/patient/pi.html. Accessed 19 Jun 2013.
196. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol. 1992;34(6):499-508.
197. Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst. 2006;98(4):273-84.
198. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992;51(1):76-89.
199. Lui SF, Chung WW, Leung CB, Chan K, Lai KN. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol. 1990;33(1):47-51.
200. Budha NR, Kovar A, Meibohm B. Comparative performance of cell life span and cell transit models for describing erythropoietic drug effects. AAPS J. 2011;13(4):650-61.
201. Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia. J Clin Pharmacol. 2010;50(5):507-20.
202. Holford N. Pharmacokinetic/pharmacodynamic models for red cell responses to hematopoietic stimulation with and without chemotherapy. American Society of Clinical Pharmacology and Therapeutics Annual Meeting; 2-5 March 2005; Orlando.
203. Heatherington AC, Henry D, Patel R, Tchekmedyian S, Berg R, Austin M, et al. The impact of timing of chemotherapy relative to darbepoetin alfa (DA) on DA pharmacokinetics (PK) and hematologic effects [abstract]. Clin Pharmacol Ther. 2004;75:P60.
204. Sasu BJ, Hartley C, Schultz H, McElroy P, Khaja R, Elliott S, et al. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. Acta Haematol. 2005;113(3):163-74.
205. Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U; ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3(2):337-47.
206. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31(5):510-8.
207. Macdougall IC. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant. 2002;17(Suppl 5):66-70.
208. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci. 1983;220(1219):141-62.
209. Van der Graaf PH, Danhof M. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther. 1997;35(10):442-6.
210. Nalbant D, Saleh M, Goldman FD, Widness JA, Veng-Pedersen P. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. J Pharmacol Exp Ther. 2010;333(2):528-32.
211. Broudy VC, Nakamoto B, Lin N, Papayannopoulou T. Dynamics of erythropoietin receptor expression on erythropoietin-responsive murine cell lines. Blood. 1990;75(8):1622-6.
212. Macdougall IC, Matcham J, Gray SJ, Group NS. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant. 2003;18(3):576-81.
213. Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2(9):1405-16.
214. Kiss Z, Elliott S, Jedynasty K, Tesar V, Szegedi J. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Eur J Clin Pharmacol. 2010;66(4):331-40.
215. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5(5):343-54.
216. Kelley LL, Koury MJ, Bondurant MC, Koury ST, Sawyer ST, Wickrema A. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood. 1993;82(8):2340-52.
217. Piron M, Loo M, Gothot A, Tassin F, Fillet G, Beguin Y. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood. 2001;97(2):442-8.
218. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1(6):1211-5.
219. Ateshkadi A, Johnson CA, Oxton LL, Hammond TG, Bohenek WS, Zimmerman SW. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1993;21(6):635-42.
220. European Medicines Agency. Aranesp: product information (2012). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000332/WC500026149.pdf. Accessed 19 Jun 2013.
221. Roche. Mircera solution for injection in pre-filled syringe: summary of product characteristics (2013). http://www.medicines.org.uk/emc/medicine/19960/ SPC/. Accessed 19 Jun 2013.